Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please explain, i dont understand your post
tx
No CC needed
Nasrat Hakim, CEO of ELITE: "MIKAH is the winner, thank you and ... you!"
I've already done it.
Nasrat said "there will be good news for Elite later" about the Sungen adderal rights.
Either, mikah merges with Elite, or Nasrat reveals the amount.
If Nasrat does not disclose the amount, this places the CEO of Elite, de facto, in a position of conflict of interest.
The price being low, he preferred to buy the 50% for himself (mikah) rather than leave them to Elite.
The price being high, he would have NO reason to hide it.
We need to put pressure on Dianne and Nasrat and get a clear answer on this.
I enjoy the analysis of N2K and I read with great interest.
However, as an investor for more than 5 years, I don't care if the turnover increases strongly or if the debts are low if the return on investment is always negative for the shareholders.
I see that the only one who does business is HAKIM / MIKAH.
I note that by not revealing the amount of rights for the adderall, Nasrat, for his own benefit, deprived Elite of making a substantial gain.
How much will its assembly in a perfect conflict of interest cost us?
the sum paid to Sungen for 50% right adderall was nor revealed, curiously by the ceo of Elite. He can said, "it was 5 millions and Elite didn't have that money". But no, we didn't know how much, was it 300.000 (like our opioid generics) or 900.000 or 2 millions?
By the way, it was too much for Elite which has never had more incomes
Elite buy breadcrumbs generics to mikah for 10 millions
Elite sold generics opioid which take money and time to develop for 300.000 dollars each
Nasrat, the CEO of Elite which have to take care of shareholders interest, buy personally the 50% of adderall (but didn't say for how much.
If Mikah didn't merge with Elite in the best interest of both parties, it is a clear conflict of interest.
Nasrat take the opportunity to buy personally for a pitance the 50% rights of adderall in place to give Elite this advantage.
Concerta is far away
Adderall is 50% in Nasrat pocket
We could make 8 millions and so what?
I told you, the deal with sungen was unfair! How much he paid for 50% adderall? How much elite will pay for it?
Post to Dianne and come back
Post to Dianne
$8,100,000
Great post!
NEXT CATALYST?
Approval Antibiotic Sungen (november)
Launch Loxapine - partner ok
Merger with Mikah or "As a matter of fact there are positive impacts on Elite that I will not go through in here today." (dixit Nasrat last CC)
100% Rights for Concerta to Elite
Any though on the timeline and development?
It's a smart post No2kolaid, thak you.
Let me be clear, I find the CURRENT situation unfair, but I agree with ANY FORM of solution, including a merger between MIKAH and ELITE.
I simply wish that this solution intervenes as quickly as possible.
In this case, the deal would be profitable for everyone, including Nasrat and the shareholders of Elite.
Mikah is not my familly.
Nasrat don't care of me.
The rights that he purchase offer NOTHING, NO ADDED VALUE to my $0,08 share.
What would be the PPS IF Nasrat make a deal to give ALL the rights for Adderall to ELITE?
Enough for me, i m waiting for the next CC
It was 50% Elite, 50% SunGen.
It's now 50% Elite, 50% CEO Elite.
Nasrat work for Elite and is paid to make value for the shareholders.
"Sungen only wants cash", but we don't know how much.
"Another company wanted to buy the rights". These are just words to justify the purchase of Nasrat.
Do you see the conflict of interest?
Just waiting for No2koolaid opinion
Thank you Aeltma
Nasrat talks a lot, but I judge people by their actions not by their words.
I did not hear him say "Elite did not have the cash to buy the rights to Sungen for Adderall which amount to the sum X, so Mikah paid the sum and the rights will go to Elite against X shares. "
Nasrat is the CEO of Elite and should defend the interests of the shareholders of Elite before his own.
As long as the CEO of Elite privatizes Sungen's rights to aderall, I find this situation unhealthy and unfair.
I think that all the shareholders should clearly indicate to Dianne and Nasrat that the rights for the Adderall constitute an added value which returns to the shareholders of elite against the payment in cash or in action of the sum paid by Nasrat to Sungen.
While the PPS is at 0.08 after years of office of the CEO, it is unacceptable that the CEO, in addition to the benefits of his function, privatizes half of the aderall's profit each quarter.
Please share your opinion and, if necessary, do like me by putting pressure on Dianne and Nasrat.
AELTMA
I do not understand very well.
This is very important, please kindly clarify the situation.
The advice of N2koolaid, Mescan and Winechimist would also be useful.
According to my understanding.
Behind the scene, Nasrat bought the rights to Sungen for the benefit of Mikah rather than that of the shareholders of Elite.
Mikah is NOT Elite.
So, every quarter, the CEO of Elite, rather than valuing the return on investment of the shareholders of Elite, will pocket half of the profits on the sale of Adderall. What a good deal for him!
That, in addition to its arrangements to take control of Elite, its salary and its bonuses.
Am I wrong on one point?
If Mikah was able to buy the share of Sungen in adderall, why did Nasrat not buy the share of Sungen for Adderall for the benefit of Elite shareholders?
Something wrong here.
We have to post and to have answer soon as possible from
Dianne Will
Telephone: 518-398-6222
Email: dianne@elitepharma.com
EXPONENTIAL REVENUES
1 million/year
5 millions/year
20 millions/year HERE, we are!
50 millions/year
100 millions/year
200 millions/year
ANYTHING HIGHER THAN 7 MILLIONS WOULD BE FANTASTIC !!![color=red][/color]
PPS $0,70 to $0,80 at the end of august
Sounds reasonable for such a positive cash flow company with high growth
Lannet and Elite to merge
Nasrat did not want to waste time and money for the concerta since Lannett already has a license to sell it. Same for loxapine.
The merger will allow a quotation on a valid market like amex, nasdaq
Nasrat will hold an honorary vice-president style position or retire with full cash.
JMO
NASRAT, TAKE THE LOWER BALL ON GOOD NEWS !!!
We cannot speculate with bad macro economics factors
Thanks for the business, but sell the company and retired in Miami
We live once
0,50$ is a minimum and will not be a problem at this time
1. THE AWAKENING
2. THE RISE OF THE DRAGON
3. FLIGHT WITH THE QUEEN
4. BILLION FOR GODS
5. SKY IS THE LIMIT
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
P/S is not the most important, market cap well. The share structure is not the same for all the public companies. Therefore, we need to compare MARKET CAP, not PRICE PER SHARE.
Nasrat tell us that only one product like adderallXR could rise the market cap to 800 millions only.
800 millions market cap, do the math per share.
NICE
10 millions+ this quarter would be a nice start!
No debt, operating cost under control, cash in hand for R&D (Sungen#4 7à millions, Sungen#5 1,5 billion,...), strong partnership, profit,...
Waiting for Loxapine and Sungen#3 antibiotic
We have a winner!
See you at dollarland soon
DO SOME MATH!
This trimestre, 10 millions+
Next fiscal year, 40 millions+
Next target, 100 millions+
HOW MUCH REVENUE THIS QUARTER?
Kscmb13 8,0 million (less than 6,5 disappointment)
Sharkey1 10,0 million
Virelle 7,3 million (less than 6,0 disappointment)
......
"It won't be long before making more income in a quarter than in a year".
HOW MUCH REVENUES THIS QUARTER?
Harder to predict than the previous quarter.
All above 6 millions would be fine for me.
Vire
N2KOOLAID
Thank you for the info.
We are still awaiting news for loxitane and approval of Sungen3 (antibiotic 94 million).
while Elite had made the commitment to file one quarterly, I can not understand the delay for the Sungen4 (70 million) and Sungen5 (1500 million).
This time lag can never be made up and money has never been an obstacle so far to adapt and develop the portfolio.
I know that the lak on cash could have differed these filing, but it is also necessary to put into perspective considering the fact that a filing is not so expensive, that we received cash by the sale of opioid products, and that Sungen5 (1,500 million) is of at least as great strategic importance as Sungen2 (1.3 trillion).
Why do I have the feeling that the filing of Sungen5 does not seem so important for Nasrat? Is this the hidden sign that it is not essential to reach a minimum objective (buyout, merger, upgrade on nasdaq, ...) or the real sign of a company whose financial balance is always precarious?
An opinion on the subject?
Finally, what income can we expect for this quarter and the next CC?
Vire
How to Calculate Your Profitability
There are two components to calculating your profitability: your gross profit and your net profit. Your gross profit is your revenue, minus the cost of goods sold (COGS). Your net profit is your gross profit minus your operating expenses.
Gross Profit
Let’s say you own a bookstore and bring in $10,000 of revenue for the month of October, but the books cost you $5,000. Your gross profit would be $5,000.
Revenue $10,000
COGS -$5,000
Gross Profit $5,000
Your gross profit is what you make off your book sales, but this calculation does not include the other costs associated with running a business, such as payroll, rent, marketing, and so on. In order to figure out your total profitability, you need to calculate your net profit.
Net Profit
If your total operating expenses for the month cost you a total of $3,000, your net profit, or your take home money, would be $2,000.
Gross Profit $5,000
Operating Expenses -$3,000
Net Profit $2,000
As you can now see more clearly, even though your cash flow and profits are related, they are not completely synonymous. Your profitability takes a look at your accounting and gives you a general overview of the bigger picture of your business’s finances. Your cash flow calculations, on the other hand, monitor your receivables and payables in real time, giving you an ongoing understanding of your monthly financial situation so you can keep operating your business from day to day.
ELITE PHARMA on the way for:
CASH FLOW POSITIVE
PROFITABILITY
GROSS PROFIT
NET PROFIT
While we are correcting some mistakes, we should also add a zero to our market cap monday morning
I find it long to approve the antibiotic sungen3. Is the FDA working in this covid period?
The time to complete Sungen4 and Sungen5 also seems to me to exceed the promise of one filing per quarter.
Damn, AMRX
1 billion market cap on NYSE
with 20 millions loss
It's time for ELTP to move on NYSE
1 billion market cap would be easy for CFP pharma
Come on Nasrat, do it!
TIMELINE SHORT TERM
LAUNCH Loxapine
APPROVAL Sungen3
FILING Sungen4
Filing Sungen5
CC JUNE 15
N2KOOLAID or AELTMA please
30 millions REVENUES for Elite pharma mean how much PROFIT (ERANINGS)???
Thank you
Lannet, 300 millions market cap, $8.00 on Nasdaq
Pharma, sales and marketing
Elite, 80 millions market cap, $0.08 on OTCCB
Pharma, generic, Sungen partnership 3 billion+
The quickest way for Elite to list on the nasdaq is to merge with Lannet. The quickest way for Lannet to grow is to merge with Elite.
The new company Elite-Lannet Pharma could quote much higher (1 billion market cap +) on the Nasdaq.
When Nasart indicated at the last conference that he would no longer be behind the microphone next time and that he was not excluded from merging with another company active in sales and marketing, the conclusion seems logical.
The parties just need to find a final agreement and a minimum of time to prepare for the merger.
Nice, thanks you
waiting for approval antibiotic and filing Sungen 4 & 5
N2KOOLAID please, could you tell us why Nasrat sold the methadone?
Thank you
Vire
THANKS MESHCAN
We are waiting in SHORT TIME:
Launch Loxapine
Approval Sungen#3, Antibiotic, 94 millions
Filing Sungen@4, antibiotic 70 millions
Filing Sungen#5, 1.500 millions
CC mid june
GO ELTP!